Abstract
Background: Prostate cancer is one the most common malignancy in men worldwide, and acinar adenocarcinoma is the most prevalent one. Gleason score and grade group is recently used to predict the therapy and prognosis based on Gleason pattern. Her-2 and Ki-67 are markers that are widely studied in breast cancer, but their role in prostate cancer is still unclear. Her-2 is a transmembrane protein involved in oncogenesis. We hope by using the basic determinant Gleason pattern to analyze the expression of these two markers, it will contribute to understand its carcinogenesis and prognosis. The aim of the study is to determine the expression of Her-2 and Ki-67 in Gleason grade of prostate acinar adenocarcinoma.Methods: An analytic observational study with cross-sectional design was done using 31 paraffin-embedded tissues of prostate acinar adenocarcinoma from the Anatomic Pathology Laboratory of Dr. Kariadi General Hospital, focusing on 48 areas classified into pattern 3, 4, and 5. Immunohistochemical staining was performed using Her-2 and Ki-67 antibodies to all tissues and the datas were analyzed using the Kruskal Wallis test and the Spearman test.Results: There are significant differences and correlations between the expression of Ki-67 and Gleason grade, but there are neither significant differences nor correlation between Her-2 expression and Gleason grade.Conclusion: Her-2 expression is almost the same among Gleason grade as basic determinant of prostate acinar adenocarcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.